These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30269054)

  • 1. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat NM; Horneff G; Kasapcopur O; Schneider R; Anton J; Barash J; Berner R; Corona F; Cuttica R; Fouillet-Desjonqueres M; Fischbach M; Foster HE; Foell D; Radominski SC; Ramanan AV; Trauzeddel R; Unsal E; Levy J; Vritzali E; Martini A; Lovell DJ;
    Ann Rheum Dis; 2018 Dec; 77(12):1710-1719. PubMed ID: 30269054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
    Brunner HI; Quartier P; Alexeeva E; Constantin T; Koné-Paut I; Marzan K; Schneider R; Wulffraat NM; Chasnyk V; Tirosh I; Kallinich T; Kuemmerle-Deschner J; Wouters C; Lauwerys B; Nikishina I; Trachana M; Vougiouka O; Martini A; Lovell DJ; Levy J; Vritzali E; Ruperto N;
    Arthritis Rheumatol; 2020 Dec; 72(12):2147-2158. PubMed ID: 32648697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
    N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
    Feist E; Quartier P; Fautrel B; Schneider R; Sfriso P; Efthimiou P; Cantarini L; Lheritier K; Leon K; Karyekar CS; Speziale A
    Clin Exp Rheumatol; 2018; 36(4):668-675. PubMed ID: 29533755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
    Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
    Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
    Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
    Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.
    Lovell DJ; Ruperto N; Mouy R; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhaes C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Huppertz HI; Job Deslandre C; Minden K; Punaro M; Block AJ; Giannini EH; Martini A;
    Arthritis Rheumatol; 2015 Oct; 67(10):2759-70. PubMed ID: 26097215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
    Quartier P; Alexeeva E; Constantin T; Chasnyk V; Wulffraat N; Palmblad K; Wouters C; I Brunner H; Marzan K; Schneider R; Horneff G; Martini A; Anton J; Wei X; Slade A; Ruperto N; Abrams K;
    Arthritis Rheumatol; 2021 Feb; 73(2):336-346. PubMed ID: 32783351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
    Brachat AH; Grom AA; Wulffraat N; Brunner HI; Quartier P; Brik R; McCann L; Ozdogan H; Rutkowska-Sak L; Schneider R; Gerloni V; Harel L; Terreri M; Houghton K; Joos R; Kingsbury D; Lopez-Benitez JM; Bek S; Schumacher M; Valentin MA; Gram H; Abrams K; Martini A; Lovell DJ; Nirmala NR; Ruperto N;
    Arthritis Res Ther; 2017 Jan; 19(1):13. PubMed ID: 28115015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
    Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
    Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
    Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
    Grom AA; Ilowite NT; Pascual V; Brunner HI; Martini A; Lovell D; Ruperto N; ; Leon K; Lheritier K; Abrams K
    Arthritis Rheumatol; 2016 Jan; 68(1):218-28. PubMed ID: 26314396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
    Nishimura K; Hara R; Umebayashi H; Takei S; Iwata N; Imagawa T; Shimizu M; Tomiita M; Seko N; Kitawaki T; Yokota S
    Mod Rheumatol; 2021 Jan; 31(1):226-234. PubMed ID: 32552266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
    Iwata N; Nishimura K; Hara R; Imagawa T; Shimizu M; Tomiita M; Umebayashi H; Takei S; Seko N; Wakabayashi R; Yokota S
    Mod Rheumatol; 2023 Nov; 33(6):1162-1170. PubMed ID: 36399020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Orrock JE; Ilowite NT
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.